The LDLR gene¹¹ LDLR gene
encodes the LDL receptor, a cell-surface protein that captures and removes LDL cholesterol from the bloodstream by binding apolipoprotein B-100 on LDL particles and shuttling them into cells for degradation. Without functional LDL receptors, circulating LDL accumulates relentlessly from birth — a condition called familial hypercholesterolemia²² familial hypercholesterolemia
the most common serious monogenic disorder, affecting ~1 in 250 people globally in its heterozygous form.

The rs763625913 variant (c.2308C>T) creates a premature stop codon at position 770 of the LDLR protein, producing a truncated, non-functional receptor. This is a receptor-negative mutation³³ receptor-negative mutation
the receptor is either not made or completely unable to bind LDL, the most severe functional class of LDLR variants. ClinVar classifies it Pathogenic for hypercholesterolemia, familial type 1⁴⁴ hypercholesterolemia, familial type 1
the autosomal dominant form caused by LDLR mutations.

The Mechanism

A nonsense mutation⁵⁵ nonsense mutation
a single DNA base change that replaces an amino acid codon with a stop codon, terminating protein synthesis prematurely at codon 770 (Gln→stop) removes the last 89 amino acids of the mature LDLR protein, which include critical domains required for receptor recycling. The truncated receptor cannot be properly expressed on the hepatocyte surface. With one defective copy (heterozygous state), approximately half the normal number of LDL receptors are present, reducing LDL clearance by ~50% and causing LDL-C to accumulate to 190–300 mg/dL⁶⁶ LDL-C to accumulate to 190–300 mg/dL
roughly 2–3× the normal range from childhood onward. The endogenous cholesterol synthesis pathway⁷⁷ endogenous cholesterol synthesis pathway
the liver continues producing cholesterol but cannot recycle the LDL fraction efficiently through the receptor pathway, compounding the problem.

The Evidence

Pathogenic LDLR nonsense and frameshift variants — the class to which Q770* belongs — are classified as receptor-negative mutations⁸⁸ receptor-negative mutations
producing no functional receptor activity. Bertolini et al. in a multicenter Italian cohort of 282 FH patients⁹⁹ Bertolini et al. in a multicenter Italian cohort of 282 FH patients
clustering mutations by regional ancestry and functional class showed that receptor-negative carriers had 18% higher LDL-C, 2.6-fold more coronary artery disease, and 2-fold more tendon xanthomas than receptor-defective carriers — confirming that complete receptor abolition is the most severe functional consequence of LDLR mutation.

Without treatment, untreated heterozygous FH carries approximately 50% cumulative coronary event risk by age 50 in men and 30% by age 60 in women¹⁰¹⁰ 50% cumulative coronary event risk by age 50 in men and 30% by age 60 in women
based on natural history registry data from the pre-statin era. The overall coronary disease excess is estimated at up to 13-fold compared to the general population¹¹¹¹ up to 13-fold compared to the general population
European Atherosclerosis Society consensus statement on FH. Critically, this risk is dramatically modifiable: high-intensity statin therapy initiated early reduces cardiovascular events by 50–80% and narrows the life expectancy gap with unaffected relatives.

This variant is extremely rare (one observation across 595,462 gnomAD exome alleles), consistent with strong purifying selection — individuals carrying it face severely elevated cardiovascular risk from birth, and reproductive fitness is reduced. Most carriers identified in clinical practice are ascertained through cascade screening after a proband is diagnosed with premature CAD or markedly elevated LDL-C.

Practical Actions

Carrying this variant is a medical diagnosis equivalent to clinically confirmed FH. The first priority is confirming the lipid phenotype with a fasting lipid panel — LDL-C is typically 190–300 mg/dL in untreated heterozygotes. High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) should be initiated regardless of age in adults, and as early as age 8–10 in affected children. The LDL-C target is <100 mg/dL for most carriers, or <70 mg/dL if coronary artery disease is already present. Because receptor-negative variants produce a more severe phenotype than receptor-defective variants, reaching these targets often requires combination therapy: high-intensity statin + ezetimibe 10 mg, and frequently a PCSK9 inhibitor¹²¹² PCSK9 inhibitor
evolocumab or alirocumab, which increase LDL receptor expression from the remaining functional allele by preventing receptor degradation.

Because FH follows autosomal dominant inheritance, every first-degree relative has a 50% chance of carrying this variant. Cascade genetic testing or LDL-C screening in parents, siblings, and children is recommended as soon as the proband is identified — early intervention in childhood prevents decades of LDL-C-driven atherosclerosis.

Interactions

This variant interacts with other cholesterol pathway variants. Carriers who also carry a PCSK9 gain-of-function variant¹³¹³ PCSK9 gain-of-function variant
e.g. rs28942080 D374Y face compounded LDL receptor dysfunction: PCSK9 rapidly degrades the residual functional LDLR protein, making pharmacologic PCSK9 inhibition especially important. Conversely, carriers of PCSK9 loss-of-function variants¹⁴¹⁴ PCSK9 loss-of-function variants
such as rs28362261 Y142X may show attenuated LDL elevation even with one defective LDLR allele, because more of the functional receptor is preserved.

Lifestyle factors modify penetrance: obesity, insulin resistance, and hypothyroidism all further impair LDL clearance and worsen the phenotype, while intensive dietary fat restriction (saturated fat below 7% of calories) can modestly reduce LDL-C by 10–15% on top of pharmacotherapy. These lifestyle modifications do not substitute for statins in this context but can assist in reaching LDL targets.

HLA-DPB1 encodes the beta chain of the HLA-DP molecule, a class II MHC receptor that presents peptide antigens to CD4+ T helper cells. This is the essential handshake that triggers adaptive immunity: without robust HLA-DP surface expression, the immune system cannot efficiently recognize viral peptides and mount a clearance response. The rs9277535 variant sits in the [3' untranslated region (3' UTR) | The regulatory sequence at the end of the mRNA transcript that controls stability, translation efficiency, and expression level — not the protein-coding region itself] of HLA-DPB1 and acts as an [eQTL | expression quantitative trait locus — a variant whose primary effect is on how much gene product is made rather than what kind] controlling transcript levels. The G allele substantially reduces HLA-DPB1 mRNA, shifting the antigen presentation dial downward.

The Mechanism

The rs9277535 G allele lies in the 3' UTR of HLA-DPB1 transcript NM_002121.6 and is in [linkage disequilibrium | Alleles at nearby positions that tend to be inherited together more often than expected by chance, so rs9277535 G tags a broader haplotype block] with functionally connected variants across the HLA-DP locus. Expression studies confirmed that the GG genotype is associated with the lowest HLA-DPB1 mRNA levels¹¹ GG genotype is associated with the lowest HLA-DPB1 mRNA levels
p=10⁻¹⁵ in 651 normal liver samples; allelic expression imbalance analysis in 17–19 heterozygotes confirmed the G allele produces less transcript than the A allele across liver tissue. Lower surface HLA-DPB1 expression translates directly to fewer antigen-presenting molecules available to engage virus-derived peptides and activate CD4+ T helper cells.

The consequence is a classic MHC trade-off: reduced HLA-DPB1 expression limits the risk of excessive immune activation (relevant to autoimmune conditions), but also limits the immune system's capacity to clear intracellular pathogens that depend on CD4+ T helper responses for viral elimination. This tension explains why rs9277535 simultaneously influences risk in opposite directions for viral infections and certain autoimmune diseases.

The Evidence

Hepatitis B clearance provides the most robustly replicated phenotype. A study of 200 Taiwanese chronic HBV patients compared those who spontaneously [cleared HBsAg | Hepatitis B surface antigen — its disappearance from blood marks functional cure of chronic infection] against persistent carriers, finding the non-GG genotype enriched in the clearance group (57% vs 42%; OR 1.83, P=0.034)²² non-GG genotype enriched in the clearance group (57% vs 42%; OR 1.83, P=0.034)
Cheng et al. 2013, PLoS One; haplotype analysis combining rs3077 and rs9277535 strengthened the OR to 2.17. Replication in an Indonesian cohort of 686 participants confirmed a protective association across a South-East Asian population (OR 0.70 additive model, P=0.026)³³ (OR 0.70 additive model, P=0.026). The underlying molecular mechanism — reduced HLA-DPB1 expression in risk allele carriers — was mechanistically established in liver eQTL analysis, directly linking the expression deficit to the antigen presentation failure that allows HBV to persist (O'Brien et al. 2011, Genes & Immunity)⁴⁴ (O'Brien et al. 2011, Genes & Immunity).

Autoimmune disease associations reveal the other side of the trade-off. In multiple sclerosis, rs9277535 shows an independent genome-wide significant association with susceptibility (combined P=2×10⁻¹⁰ across 3,830 MS cases and 5,664 controls)⁵⁵ (combined P=2×10⁻¹⁰ across 3,830 MS cases and 5,664 controls) driven by the correlation with HLA-DPB1*03:01 — a specific protein allotype linked to MS in earlier candidate-gene studies. For rheumatoid arthritis, the picture reflects the expression axis clearly: in Chinese Han patients, the A allele (higher HLA-DPB1 expression) was associated with increased RA susceptibility (OR 1.409, P=0.004; 254 RA cases, 391 controls)⁶⁶ (OR 1.409, P=0.004; 254 RA cases, 391 controls) and elevated anti-CCP antibodies, while the G allele (lower expression) was protective⁷⁷ G allele (lower expression) was protective
OR for protective effect confirmed in 805 RA patients vs 1,095 controls; AG and GG genotypes associated with lower plasma HLA-DPB1 levels. This inverse relationship — the same allele that reduces HBV clearance reduces RA risk — is the hallmark of [balancing selection | Evolutionary pressure maintaining both alleles in a population because heterozygotes have an advantage over either homozygote, common in MHC genes exposed to conflicting infectious and autoimmune pressures] at the MHC locus.

Practical Actions

The G allele's primary actionable consequence is impaired HBV clearance capacity. GG homozygotes have lower HLA-DPB1 surface expression, producing a weaker CD4+ T helper response to hepatitis B antigens. This translates to reduced natural clearance after HBV exposure and, importantly, reduced vaccine response — HBV vaccine efficacy depends on the same antigen presentation machinery this variant diminishes. AA individuals who carry two copies of the higher-expression A allele have efficient antigen presentation but carry elevated susceptibility to autoimmune conditions like RA in populations where this trade-off is clinically relevant.

The G allele is substantially more common in East Asian populations (~62% allele frequency vs ~24% in Europeans), which aligns with the higher burden of HBV chronic infection in East Asian countries and the known population-stratified effects of HLA-DP variants on HBV outcomes. Because G allele carriers may mount suboptimal vaccine responses, verifying seroconversion after HBV vaccination is a specific, genotype-informed recommendation.

Interactions

rs9277535 interacts with rs3077 (in the 3' UTR of the neighboring HLA-DPA1 gene) to form a combined HLA-DP haplotype. The GA haplotype (rs3077 G + rs9277535 A) showed a stronger association with HBV clearance than either SNP alone (OR 2.17 vs 1.83 for rs9277535 alone). The two SNPs co-regulate the HLA-DPA1/DPB1 heterodimer — the functional antigen presentation unit — meaning that variation in both alpha and beta chains together determines the overall antigen presentation phenotype. The nearby rs9277534 (496A/G) tags a different haplotype block with partially overlapping effects. For a comprehensive HLA-DP antigen presentation assessment, both rs3077 and rs9277535 should be interpreted together.

Inside every primary oocyte, a protein called SYCP2L quietly anchors chromosomes to their meiotic pairing sites. When the synaptonemal complex assembles during prophase I — the critical period when maternal and paternal chromosomes zip together and exchange genetic material — SYCP2L acts as a structural anchor, localising specifically to oocyte centromeres. Without it, chromosomes pair imperfectly, recombination fails, and eggs accumulate meiotic errors that ultimately deplete the ovarian reserve faster than normal.

rs9348724 sits 2 kilobases upstream of SYCP2L, in a regulatory region that influences the gene's expression. The minor C allele at this position is associated with a later age at natural menopause — roughly 0.26 additional years per C copy. Because the GG genotype is the global majority (carried by about 65% of European women), most people experience average menopause timing; those with one or two copies of the C allele tend to retain functional ovarian reserve somewhat longer.

The Mechanism

SYCP2L is a paralogue of synaptonemal complex protein 2¹¹ paralogue of synaptonemal complex protein 2
SYCP2 — the canonical lateral element component that is expressed exclusively in oocytes and localises to primordial follicle centromeres. In SYCP2L-knockout female mice, primordial oocyte pools deplete progressively with age at a rate significantly faster than wild-type controls, and fertility declines earlier. The defect traces to impaired centromere fidelity during meiotic prophase, leading to spindle misalignment and downstream chromosome segregation errors.

The rs9348724 locus is a regulatory variant, not a coding change, so its effect operates through altered SYCP2L expression levels rather than a structural protein change. The C allele is hypothesised to support slightly higher or more sustained SYCP2L expression, maintaining centromere integrity over a longer reproductive lifespan. At the severe end, homozygous loss-of-function mutations in SYCP2L cause premature ovarian insufficiency (POI) — amenorrhoea with elevated FSH before age 40 — demonstrating that full SYCP2L function is necessary for normal ovarian longevity.

The Evidence

The primary association comes from Ruth et al. 2021²² Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393–397, the largest menopause GWAS to date (201,323 women). rs9348724 reached genome-wide significance at p = 4×10⁻¹¹² with a beta of +0.255 years per C allele — one of the strongest single-variant effects in the study. The paper implicates the broader meiotic DNA damage response and synaptonemal complex assembly pathway as a key determinant of ovarian ageing pace.

The functional story was established by Zhou et al. 2015³³ Zhou et al. 2015
Accelerated reproductive aging in females lacking a novel centromere protein SYCP2L. Hum Mol Genet, who showed that SYCP2L-knockout mice lose primordial oocytes at an accelerated rate and have reduced litter sizes. In humans, the intronic rs2153157 splice variant at the same locus changes U12-type minor intron splicing efficiency, with the more-efficiently-spliced allele associating with delayed menopause. Together, these findings converge on the conclusion that SYCP2L dose matters for reproductive lifespan.

At the clinical extreme, He et al. 2021⁴⁴ He et al. 2021
J Med Genet identified homozygous loss-of-function SYCP2L mutations in POI patients, confirming the gene as a bona fide cause of ovarian failure. Rosa et al. 2023⁵⁵ Rosa et al. 2023
JBRA Assist Reprod further showed that SYCP2L rs2153157 AA genotype correlates with significantly lower anti-Müllerian hormone (AMH) levels (p=0.01), a direct biomarker of ovarian reserve, in IVF patients.

Practical Actions

For women carrying two copies of the common G allele (GG), there is no specific intervention required — ovarian reserve follows the population-average trajectory. Monitoring AMH and antral follicle count before age 35 can establish a personal baseline, particularly if family history suggests early menopause.

Coenzyme Q10 has the strongest evidence for supporting oocyte mitochondrial quality during the meiotic process. Ben-Meir et al. 2015⁶⁶ Ben-Meir et al. 2015 demonstrated that age-related oocyte quality decline — driven by reduced CoQ10 biosynthesis and impaired mitochondrial ATP production — is reversible with CoQ10 supplementation in mouse models, with reduced spindle misalignment in treated animals. In a human RCT, Xu et al. 2018⁷⁷ Xu et al. 2018 showed that 60 days of CoQ10 pretreatment improved oocyte retrieval numbers, fertilisation rates, and embryo quality in women with poor ovarian reserve. A 2024 meta-analysis of 20 RCTs identified 30 mg/day for 3 months prior to stimulation as the optimal protocol for improving pregnancy rates.

Interactions

The strongest interaction at this locus is with rs2153157, another SYCP2L variant (intronic, affecting splice efficiency) that independently associates with menopause timing. Both rs9348724 and rs2153157 are within the same gene and likely act through shared expression regulation, but they are not in complete LD — a user carrying the beneficial allele at one position may or may not carry it at the other.

Downstream pathway interactions are worth noting: impaired synaptonemal complex assembly sensitises oocytes to DNA double-strand break accumulation. Variants in DNA repair genes (e.g. MCM8, BRCA2 pathway components) that also associate with menopause timing in the Ruth 2021 GWAS may compound effects on oocyte longevity.

Your immune system uses a signaling molecule called IL-33¹¹ IL-33
Interleukin-33, a cytokine released by damaged epithelial cells lining the airways, skin, and gut — it acts as an early-warning alarm for allergens, parasites, and tissue injury to raise the alarm when the body's barrier tissues are threatened. IL1RL1 encodes the ST2 receptor that detects this alarm. But the gene also produces a second, soluble form of the receptor — sST2 — that floats freely in the bloodstream and acts as a decoy, intercepting IL-33 before it can activate immune cells. The balance between membrane-bound ST2 (which passes the alarm signal through) and soluble sST2 (which silences it) is a critical tuning dial for type 2 immune responses. rs1420101 sits at that dial.

The Mechanism

rs1420101 is an intronic eQTL²² eQTL
expression quantitative trait locus — a genetic variant that controls how much of a gene's product is made, rather than changing the protein structure itself in airway epithelial cells. The T risk allele shifts the expression balance away from the soluble sST2 decoy and toward the membrane-bound signaling form. With less circulating sST2 to intercept it, IL-33 reaches immune cells more readily, driving type 2 inflammation³³ type 2 inflammation
A class of immune response dominated by eosinophils, mast cells, and IgE, characteristic of asthma, hay fever, eczema, and nasal polyps. The effect is dose-dependent: each copy of the T allele progressively lowers sST2. The C allele has the opposite effect — it is the strongest known pQTL for circulating sST2 protein, with the association reaching p=2.8×10⁻⁵⁶ in over 1,400 participants.

The Evidence

The IL1RL1 locus is one of the most replicated genetic signals in atopic disease. Ferreira et al. (Nature Genetics, 2017)⁴⁴ Ferreira et al. (Nature Genetics, 2017)
Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nature Genetics 49:1752–1757 identified the locus among the top shared risk signals in a meta-analysis of 360,838 individuals, confirming that the same variant influences asthma, hay fever, and eczema together — not as separate diseases but as expressions of a shared underlying biology.

Demenais et al. (Nature Genetics, 2018)⁵⁵ Demenais et al. (Nature Genetics, 2018)
Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics 50:42–53 quantified the T allele effect at OR 1.12 (p=4×10⁻²¹) for asthma in a multi-ethnic dataset.

Gordon et al. (JCI Insight, 2016)⁶⁶ Gordon et al. (JCI Insight, 2016)
IL1RL1 asthma risk variants regulate airway type 2 inflammation provided the mechanistic link: in airway epithelial cells from 127–141 individuals, T allele carriers showed lower sST2 expression under both baseline and IL-13-stimulated conditions. Carriers of 3–4 risk alleles across rs1420101 and the nearby rs11685480 had an OR of 2.85 for the type-2-high asthma endotype.

Dijk et al. (Eur Respir J, 2018)⁷⁷ Dijk et al. (Eur Respir J, 2018)
Genetic regulation of IL1RL1 methylation and IL1RL1-a protein levels in asthma confirmed the pQTL signal in 1,462 participants — rs1420101 is the dominant genetic driver of circulating sST2 levels, explaining a substantial fraction of inter-individual variability.

Clinically, the TT genotype has been linked to better outcomes with targeted biologic therapy: Nishi et al. (ERJ Open Res, 2025)⁸⁸ Nishi et al. (ERJ Open Res, 2025)
IL1RL1 variant may affect the response to type 2 biologics in patients with severe asthma found that TT carriers achieved excellent Global Evaluation of Treatment Effectiveness (GETE) scores on benralizumab and other anti-IL-5 therapies, making the variant a candidate pharmacogenomic predictor. The biological logic is direct: TT genotype → low sST2 → high IL-33 signaling → eosinophil-driven inflammation → high sensitivity to eosinophil-depleting anti-IL-5 blockade.

Practical Actions

For CC homozygotes, the high circulating sST2 acts as an effective IL-33 buffer — standard allergen avoidance and treatment approaches are sufficient. For CT and TT carriers, the reduced decoy receptor buffer means the threshold for IL-33-driven inflammation is lower, which translates to practical differences in monitoring and trigger management.

TT carriers with severe asthma who have not responded well to inhaled corticosteroids or leukotriene antagonists may benefit from earlier consideration of anti-IL-5 biologics, given the evidence of TT-genotype-specific response. sST2 serum measurement is available as a clinical biomarker — it is routinely measured in heart failure monitoring and can reflect IL-33 pathway activity across conditions.

Interactions

The strongest documented interaction is with the nearby IL1RL1 variant rs11685480. Gordon et al. (2016) showed that combining T alleles at rs1420101 with risk alleles at rs11685480 yields an OR of 2.85 for type-2-high asthma — substantially greater than either variant alone. The two SNPs tag partially overlapping but independent signals within the gene's regulatory architecture. A compound action capturing the combined risk of carrying T alleles at both loci would be informative for severe asthma risk stratification and biologic therapy selection.

IL-33 pathway variants in the upstream IL33 gene (including rs992969 and rs1929992) can further amplify risk by increasing the amount of IL-33 ligand that must be buffered by sST2.

Most genes do one job. GLIS3 (GLIS family zinc finger 3) does two: it is a master transcription factor required for the development of both thyroid follicular cells and pancreatic beta cells. Rare loss-of-function mutations in GLIS3 cause a syndrome of neonatal diabetes combined with congenital hypothyroidism — a clinical double-hit that reveals just how foundational this single gene is to two of the body's most metabolically critical tissues. The common rs1571583 variant is a far subtler version of the same signal: a population-frequency intronic variant in which one allele nudges thyroid stimulating hormone upward, shifting the thyroid setpoint in a direction associated with lower metabolic rate, greater fat accumulation tendency, and modestly elevated type 2 diabetes risk.

The Mechanism

rs1571583 lies within an intron of GLIS3 on chromosome 9p24.2. It does not change the protein sequence but is believed to influence GLIS3 expression levels in a tissue-specific manner, consistent with the regulatory architecture of its chromosomal neighbourhood. GLIS3 protein controls transcription of the thyroid-specific genes needed for thyroid follicle formation and thyroid hormone synthesis — including thyroglobulin (TG) and sodium/iodide symporter (SLC5A5/NIS). Even subtle reductions in GLIS3 activity in the thyroid translate into less efficient thyroid hormone output, prompting the pituitary to release more [TSH (thyroid stimulating hormone) | TSH is secreted by the anterior pituitary in response to low circulating T3/T4; it stimulates the thyroid gland to produce and release thyroid hormones, completing a classic negative-feedback endocrine loop] to drive compensatory output. The result is a higher TSH setpoint without overt hypothyroidism — but measurably less metabolic efficiency.

In the pancreas, GLIS3 activates neurogenin 3 (NGN3) in cooperation with HNF6 and FOXA2 to drive fetal islet differentiation, and it maintains adult beta cell function by co-operating with PDX1, MAFA, and NEUROD1 on the insulin gene promoter. GLIS3 is also required for compensatory beta cell mass expansion when insulin resistance develops. Variants that mildly reduce GLIS3 expression therefore create a dual vulnerability: a slightly less responsive thyroid axis and a reduced capacity for beta cell compensation under metabolic stress.

The Evidence

The foundational population study was a meta-analysis of thyroid-related traits by Porcu et al.¹¹ meta-analysis of thyroid-related traits by Porcu et al.
Porcu E et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet 2013 in 26,420 euthyroid subjects. GLIS3 was identified as one of 15 novel genome-wide significant TSH loci; the A allele at rs1571583 was associated with higher TSH (beta +0.057 per allele copy, p=2.55×10⁻⁸). The effect is modest per allele, but measurable — two A alleles shift the TSH distribution upward by roughly 0.11 units, a difference detectable within the normal reference range. The study also found that the GLIS3 locus, along with four other loci, showed gender-specific differences in its effect on thyroid function, with the TSH-raising effect appearing somewhat stronger in males (beta +0.074, p=1×10⁻⁶ in male-stratified analysis).

A 2023 study by Mulder et al.²² Mulder et al.
Mulder TA et al. Genetic determinants of thyroid function in children. Eur J Endocrinol 2023 found that among 60 thyroid-function SNPs, the GLIS3 locus showed notably larger effect sizes in children compared to adults — consistent with GLIS3's well-documented developmental role in thyroid differentiation during fetal and early postnatal life.

The diabetes connection is supported by a body of work on GLIS3's functional requirement in beta cells. Wen and Yang's review³³ Wen and Yang's review
Wen X, Yang Y. Emerging roles of GLIS3 in neonatal diabetes, type 1 and type 2 diabetes. J Mol Endocrinol 2017 summarises that GWAS data show GLIS3 variants are associated with both T1D and T2D, and that GLIS3 is required for compensatory beta cell mass expansion under insulin resistance — meaning individuals with reduced GLIS3 activity may have a reduced buffer capacity when metabolic demand rises. A 2024 study in Diabetologia⁴⁴ 2024 study in Diabetologia
Meulebrouck S et al. Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk. Diabetologia 2024 found that rare pathogenic GLIS3 variants confer OR 2.1 [95% CI 1.4-2.9] for T2D — a strong functional validation that GLIS3 loss-of-function is causally linked to diabetes.

Practical Actions

For A-allele carriers, the primary actionable implication is the elevated TSH tendency. High-normal TSH — even within the reference range — is associated with slower metabolic rate, a tendency toward weight gain, impaired lipid clearance, and reduced thermogenesis. Iodine and selenium are the two dietary micronutrients with the most evidence-backed roles in thyroid hormone synthesis and peripheral conversion: iodine as the essential substrate for T3/T4 biosynthesis, selenium as a cofactor for the deiodinase enzymes that convert T4 into the active T3 form. A-allele carriers who already have high-normal TSH should ensure adequate — but not excessive — dietary iodine and confirm their selenium status, since selenium deficiency compounds thyroid underactivity.

Periodic TSH monitoring is warranted because the A allele shifts the setpoint upward; over time, what starts as high-normal TSH can drift into subclinical hypothyroidism, particularly with age or pregnancy. Annual TSH testing identifies this drift before symptoms (fatigue, cold intolerance, weight gain) develop.

Interactions

GLIS3 sits at the intersection of two major endocrine systems. Within the thyroid axis, rs903814 (another GLIS3-region variant) has been independently associated with TSH in some populations, and the two may jointly influence the GLIS3 expression setpoint. Within the pancreatic beta cell axis, GLIS3 function intersects with TCF7L2 (rs7903146) — the strongest common T2D locus — since both regulate beta cell mass and insulin gene transcription. Carriers of both a reduced-function GLIS3 allele and a TCF7L2 risk allele may face compounded reduction in beta cell reserve capacity, though direct published evidence for this specific combination is not yet available.

The related GLIS3 variants rs7034200 and rs7041847 have been associated with fasting glucose and T2D risk in East Asian GWAS studies and likely tag the same functional haplotype through their LD with rs1571583.

Glutathione S-transferase Pi 1 (GSTP1) is one of the most important Phase II detoxification enzymes¹¹ Phase II detoxification enzymes
Phase II enzymes conjugate activated toxins with water-soluble molecules (like glutathione) so they can be excreted in urine or bile. Phase I enzymes activate toxins; Phase II neutralizes them. in the human body. It catalyzes the conjugation of glutathione²² glutathione
A tripeptide (glutamate-cysteine-glycine) that is the body's master antioxidant and primary substrate for Phase II detoxification reactions to a broad range of electrophilic compounds -- carcinogens, chemotherapy drugs, products of oxidative stress, and environmental pollutants including heavy metals. GSTP1 provides the majority of GST activity in the lung and is widely expressed in the liver, kidneys, and gastrointestinal tract.

The rs1695 variant causes an isoleucine-to-valine substitution at position 105 (Ile105Val), right in the hydrophobic substrate-binding pocket (H-site)³³ hydrophobic substrate-binding pocket (H-site)
The H-site is the region of the enzyme that physically contacts the electrophilic substrate. Position 105 sits on a helix alongside Tyr109, and together they define the shape and chemistry of the binding cleft. of the enzyme. This single amino acid change reshapes the active site geometry, fundamentally altering which substrates the enzyme handles efficiently -- and which it does not.

The Mechanism

The Val105 substitution has a paradoxical effect on enzyme function that depends on the substrate. For the general-purpose model substrate CDNB⁴⁴ CDNB
1-chloro-2,4-dinitrobenzene, a standard laboratory substrate used to measure GST activity broadly, the Val105 enzyme is approximately three-fold less active⁵⁵ three-fold less active
The essential role of GSTP1 I105V polymorphism in the prediction of CDNB metabolism and toxicity: In silico and in vitro insights. Toxicol In Vitro, 2023 than the Ile105 form. However, for the diol epoxides of polycyclic aromatic hydrocarbons (PAHs)⁶⁶ diol epoxides of polycyclic aromatic hydrocarbons (PAHs)
Reactive metabolites of combustion products found in cigarette smoke, grilled meat, and vehicle exhaust; benzo[a]pyrene diol epoxide (BPDE) is the most studied, the Val105 enzyme shows seven-fold higher catalytic efficiency⁷⁷ seven-fold higher catalytic efficiency
Watson MA et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis, 1998 compared to the Ile105 form. This substrate-dependent shift means carriers of the Val105 allele process PAH carcinogens more efficiently but have reduced capacity for many other electrophilic toxins and oxidative stress products.

The variant also affects the enzyme's thermal stability -- the Val105 protein is less stable than the Ile105 form, which may reduce the total pool of functional GSTP1 protein available for detoxification under physiological conditions.

Critically, GSTP1 also metabolizes sulforaphane⁸⁸ sulforaphane
The principal bioactive isothiocyanate from cruciferous vegetables (broccoli, kale, Brussels sprouts). Sulforaphane activates the Nrf2 pathway, which upregulates dozens of detoxification and antioxidant enzymes., the key compound from cruciferous vegetables that activates the Nrf2/ARE pathway⁹⁹ Nrf2/ARE pathway
Nuclear factor erythroid 2-related factor 2 / Antioxidant Response Element -- the master regulator of cellular antioxidant defense. When activated, Nrf2 drives expression of over 200 cytoprotective genes.. The Val105 variant has reduced specific activity toward sulforaphane, which paradoxically may allow more sulforaphane to reach its target (Nrf2) rather than being conjugated and eliminated. This creates a complex interplay between genotype and dietary intervention.

The Evidence

Cancer risk. The most robust evidence comes from a Shanghai Breast Cancer Study¹⁰¹⁰ Shanghai Breast Cancer Study
Parl FF et al. Cruciferous vegetables, the GSTP1 Ile105Val genetic polymorphism, and breast cancer risk. Am J Clin Nutr, 2008 of 3,035 cases and 3,037 controls, which found that the Val/Val genotype was associated with a 1.50-fold increased breast cancer risk (OR 1.50, 95% CI 1.12-1.99), with the effect strongest in premenopausal women (OR 2.08). A meta-analysis of 51 studies¹¹¹¹ meta-analysis of 51 studies
Wei B et al. Association between GSTP1 Ile105Val polymorphism and urinary system cancer risk. Onco Targets Ther, 2016 covering 11,762 cases and 15,150 controls found that Val allele carriers had increased prostate cancer risk (OR 1.80, 95% CI 1.19-2.73) and elevated bladder cancer risk across multiple genetic models (GG vs AA: OR 1.49, 95% CI 1.12-1.97).

Chemotherapy toxicity. GSTP1 directly metabolizes platinum-based chemotherapy drugs. A meta-analysis by Lv et al.¹²¹² meta-analysis by Lv et al.
Lv F et al. Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs. J Int Med Res, 2018 found that G allele carriers had 1.7-fold higher hematological adverse events and 2.6-fold higher neutropenia risk during platinum chemotherapy compared to the AA genotype. The variant also predicts cyclophosphamide-induced toxicity¹³¹³ cyclophosphamide-induced toxicity
Mokhtar GM et al. Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities. Genes Environ, 2021 including myelosuppression and gastrointestinal side effects.

Heavy metal detoxification. GSTP1 plays a direct role in conjugating heavy metals with glutathione for elimination. A study by Santos et al.¹⁴¹⁴ study by Santos et al.
Santos A et al. The GSTP1 rs1695 polymorphism is associated with mercury levels and neurodevelopmental delay in indigenous Munduruku children. Toxics, 2024 found that the rs1695 polymorphism was associated with mercury levels and neurodevelopmental outcomes, while in vitro studies show that heavy metals can directly inhibit GST variants differently¹⁵¹⁵ heavy metals can directly inhibit GST variants differently
Paiva L et al. Variants of glutathione S-transferase pi 1 exhibit differential enzymatic activity and inhibition by heavy metals. Toxicol In Vitro, 2012, with the Val105 form showing altered sensitivity to mercury and cadmium inhibition.

Oxidative stress and airway inflammation. The Val105 variant modulates allergen-provoked airway inflammation in asthmatics. A controlled allergen challenge study¹⁶¹⁶ controlled allergen challenge study
Fryer AA et al. Glutathione S-transferase P1 Ile105Val polymorphism modulates allergen-induced airway inflammation in human atopic asthmatics in vivo. Clin Exp Allergy, 2013 found that Val105/Val105 asthmatics had greater generation of acute-phase cytokines and inflammatory mediators after allergen challenge compared to other genotypes, indicating reduced capacity to buffer oxidative stress in the airways.

Practical Implications

The most actionable finding for everyday health is the interaction between GSTP1 genotype and cruciferous vegetable intake. The Shanghai study showed that women with Val/Val genotype and low cruciferous vegetable intake had 1.74-fold increased breast cancer risk, but high cruciferous intake substantially ameliorated this risk. Since the Val105 enzyme is less efficient at conjugating sulforaphane, more of this beneficial compound may actually reach its Nrf2 target -- but only if you eat enough cruciferous vegetables to begin with.

For individuals carrying one or two G alleles, supporting the body's glutathione system becomes particularly important. This means ensuring adequate intake of glutathione precursors (N-acetylcysteine, glycine, glutamine), selenium (a cofactor for glutathione peroxidase), and antioxidant-rich foods. Minimizing unnecessary exposures to environmental toxins -- especially tobacco smoke, which contains PAHs -- is also relevant, though the Val105 form is actually more efficient at clearing PAH metabolites specifically.

For anyone undergoing platinum-based chemotherapy or cyclophosphamide treatment, this variant should be discussed with the oncology team, as it may affect drug metabolism and toxicity risk.

Interactions

The most direct interaction is with rs1138272 (GSTP1 Ala114Val), another variant in the same enzyme. Together, these two SNPs define the GSTP1 haplotypes: GSTP1*A (Ile105/Ala114, wild-type), GSTP1*B (Val105/Ala114), and GSTP1*C (Val105/Val114). The GSTP1*C haplotype, carrying both variant alleles, has been associated with a 5.46-fold increased prostate cancer risk compared to GSTP1*A. The two variants are separated by approximately 1 kb with moderate linkage disequilibrium (D' approximately 0.48), so they segregate partially independently.

GSTP1 also interacts with the other major glutathione S-transferase genes -- GSTM1 and GSTT1 -- which can be completely deleted (null genotypes). The combination of GSTM1 null, GSTT1 null, and GSTP1 Val105 creates a severely compromised glutathione conjugation capacity. Studies have found up to 6-8-fold increased risk for bladder cancer and other malignancies when all three GST pathways are impaired simultaneously.

The KIBRA¹¹ KIBRA
KIdney and BRAin expressed protein, also known as WWC1 (WW and C2 domain containing 1) gene encodes a postsynaptic scaffolding protein that plays a central role in memory formation. In 2006, a genome-wide association study made KIBRA the first gene linked to normal variation in human memory performance through unbiased genomic scanning. A common C-to-T change in intron 9 (rs17070145) was associated with significantly better episodic memory — the ability to recall specific events and experiences. T allele carriers showed 24% better free recall at 5 minutes and 19% better recall at 24 hours compared to CC homozygotes.

The Mechanism

KIBRA protein is highly expressed in the hippocampus and other memory-related brain regions. It functions as a molecular scaffold at postsynaptic densities²² postsynaptic densities
The protein-rich region at the receiving end of a synapse, where neurotransmitter signals are received and processed, where it anchors the enzyme PKMzeta³³ PKMzeta
Protein kinase M-zeta, an atypical protein kinase C isoform that maintains long-term potentiation — the cellular basis of memory at activated synapses. This KIBRA-PKMzeta complex sustains long-term potentiation (LTP)⁴⁴ long-term potentiation (LTP)
The persistent strengthening of synaptic connections, widely considered the cellular mechanism underlying learning and memory by regulating postsynaptic AMPA receptors⁵⁵ AMPA receptors
Glutamate receptors that mediate fast synaptic transmission; their trafficking to and from the synapse controls synaptic strength, keeping synaptic connections strong after learning.

KIBRA also binds to dendrin⁶⁶ dendrin
A postsynaptic protein enriched in the hippocampus that helps organize the postsynaptic density with nanomolar affinity via its WW domains, and this interaction regulates KIBRA's localization to synapses. Additionally, KIBRA participates in the MAPK signaling pathway⁷⁷ MAPK signaling pathway
Mitogen-activated protein kinase pathway, a chain of proteins that communicates signals from the cell surface to the nucleus, involved in synaptic plasticity, which is differentially activated in the hippocampus depending on rs17070145 genotype.

Although rs17070145 sits in an intron and does not directly change the protein sequence, it is in complete linkage disequilibrium⁸⁸ linkage disequilibrium
When two genetic variants are inherited together more often than expected by chance, meaning one variant can serve as a proxy for the other with two missense variants in exon 15 (M734I and S735A) that alter the KIBRA C2 domain's lipid-binding capacity. These linked coding changes likely represent the functional mechanism through which the intronic SNP influences memory.

The Evidence

The original discovery⁹⁹ original discovery
Papassotiropoulos A et al. Common Kibra alleles are associated with human memory performance. Science, 2006 screened over 500,000 SNPs in 341 young Swiss adults and found rs17070145 to be significantly associated with delayed free recall, then replicated the finding in two additional cohorts from Switzerland (n=424) and the United States (n=256). Gene expression confirmed KIBRA was expressed in memory-related brain structures.

A comprehensive meta-analysis¹⁰¹⁰ comprehensive meta-analysis
Milnik A et al. Association of KIBRA with episodic and working memory: a meta-analysis. Am J Med Genet B, 2012 pooling 17 samples (N=8,909 for episodic memory, N=4,696 for working memory) confirmed the association. The T allele explained 0.5% of variance in episodic memory (r=0.068, P=0.001) and 0.1% of variance in working memory (r=0.035, P=0.018). While these effect sizes are small in absolute terms, they are among the largest for any common variant affecting normal cognitive variation.

Functional neuroimaging¹¹¹¹ Functional neuroimaging
Kauppi K et al. KIBRA polymorphism is related to enhanced memory and elevated hippocampal processing. J Neurosci, 2011 revealed that T carriers show increased right hippocampal activation during memory retrieval compared to CC homozygotes, even after matching for age, sex, and performance level. Structural MRI studies have also found that T carriers have larger hippocampal volumes¹²¹² larger hippocampal volumes
Palombo DJ et al. KIBRA polymorphism is associated with individual differences in hippocampal subregions. J Neurosci, 2013, specifically in the CA fields and dentate gyrus — regions critical for memory encoding.

A meta-analysis of 20 case-control studies¹³¹³ meta-analysis of 20 case-control studies
Ling J et al. Association of KIBRA polymorphism with risk of Alzheimer's disease. Neurosci Lett, 2018 found that CC homozygotes had a modestly increased risk of Alzheimer's disease compared to T carriers (OR=1.23 in the homozygote model, OR=1.14 in the dominant model), particularly among older individuals. Recent research has illuminated why: the KIBRA C-terminal fragment repairs synaptic plasticity¹⁴¹⁴ repairs synaptic plasticity
Kauwe G et al. KIBRA repairs synaptic plasticity and promotes resilience to tauopathy-related memory loss. J Clin Invest, 2024 disrupted by pathogenic tau protein, suggesting KIBRA-mediated synaptic maintenance may protect against neurodegeneration.

Practical Implications

The effect of rs17070145 on memory is real but modest — this is not a gene that determines whether you have a "good" or "bad" memory. The 0.5% of variance explained means that hundreds of other genetic and environmental factors matter far more for your overall memory ability. Education, sleep, exercise, social engagement, and cognitive activity all have substantially larger effects on memory performance than any single common genetic variant.

That said, understanding your KIBRA genotype can inform your approach to brain health. CC homozygotes may benefit more from proactive cognitive maintenance strategies, while T carriers can take some reassurance that their baseline synaptic plasticity machinery is operating efficiently. For everyone, the same lifestyle factors that support general brain health — sustained cardio (cycling, swimming, brisk walking), quality sleep, cognitive challenge, and social connection — also support the synaptic plasticity pathways that KIBRA participates in.

The Alzheimer's association adds a long-term dimension: while the absolute risk increase for CC homozygotes is small, it provides additional motivation for lifelong brain health habits, especially in combination with other risk factors.

Interactions

KIBRA rs17070145 interacts with APOE genotype in the context of Alzheimer's risk. Research in 602 cognitively normal adults followed over six years found that APOE epsilon-4 carriers who were also CC homozygotes at rs17070145 showed significantly faster rates of cognitive decline and hippocampal atrophy when amyloid-beta burden was high, compared to T carriers. The T allele appeared to confer resilience against the detrimental effects of APOE epsilon-4 and amyloid accumulation.

KIBRA also interacts with CLSTN2 (calsyntenin 2, rs6439886). The memory-enhancing effect of the KIBRA T allele is modulated by CLSTN2 genotype, with the two genes showing interactive effects on episodic memory performance. Both proteins are involved in synaptic plasticity pathways in the hippocampus.

PPARG¹¹ Full name: Peroxisome Proliferator-Activated Receptor Gamma is a nuclear receptor²² Nuclear receptors are proteins that bind to DNA and directly regulate gene expression in response to hormones and metabolites that regulates fatty acid storage and glucose metabolism. It's the target of thiazolidinedione³³ Thiazolidinediones (e.g. pioglitazone) are diabetes drugs that work by activating PPARG to improve insulin sensitivity drugs used to treat type 2 diabetes.

The Mechanism

The Pro12Ala variant (rs1801282) is a missense mutation in exon B of PPARG, where a cytosine-to-guanine change substitutes proline with alanine at position 12 (p.Pro12Ala). This occurs in the ligand-independent activation domain of the PPARγ2 isoform. The Ala (G) allele reduces PPARG transcriptional activity slightly, which paradoxically improves insulin sensitivity — likely because excessive PPARG activity promotes fat storage.

The Evidence

The original discovery by Deeb et al.⁴⁴ original discovery by Deeb et al.
Deeb et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998 demonstrated that the Ala allele reduces receptor activity and is associated with lower BMI and better insulin sensitivity in Finnish populations.

Altshuler et al.⁵⁵ Altshuler et al.
Altshuler et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet, 2000 confirmed in over 3,000 individuals that the common Pro allele (C) carries a modest 1.25-fold increase in diabetes risk compared to the Ala allele (G).

A HuGE meta-analysis of 60 studies⁶⁶ HuGE meta-analysis of 60 studies
Gouda et al. The association between the PPARG2 Pro12Ala gene variant and T2DM. Am J Epidemiol, 2010 involving 32,849 cases and 47,456 controls confirmed the protective effect of Ala12 (OR 0.86).

Practical Implications

The Pro (C) allele is the common variant (~75% of Europeans are CC). Having one or two copies of the Ala (G) allele is protective — it improves how your cells respond to insulin. The G allele is rare in African populations (~1%) but more common in European and South Asian populations (~11-12%).

Interactions

PPARG interacts with TCF7L2 (rs7903146) in determining overall diabetes risk. If you carry the protective Ala allele here but the risk T allele at TCF7L2, the effects may partially offset each other. PPARG is also the target of thiazolidinedione drugs — carriers of Ala12 may respond differently to these medications.

CYP2C9 is one of the most clinically important drug-metabolizing enzymes in the human body, responsible for clearing roughly 15-20% of all clinically used pharmaceuticals ¹¹ CYP2C9 substrate drugs include warfarin, phenytoin, NSAIDs, and multiple sulfonylurea antidiabetics. The well-known functional variants CYP2C9*2 (rs1799853) and *3 (rs1057910) reduce enzyme activity by 50-90% and are the subject of CPIC and FDA pharmacogenomic guidance for warfarin and phenytoin. rs1934963 adds a deeper layer to this picture: a deep intronic variant sitting 2,674 nucleotides into intron 7 (NM_000771.4:c.961+2674T>C) that has emerged as an independent signal for variable drug response in CYP2C9-substrate medications.

The Mechanism

Unlike CYP2C9*2 and *3, which directly alter the enzyme's active site through amino acid substitutions, rs1934963 lies within a non-coding intronic region and causes no protein change. Deep intronic variants can affect drug metabolism through several mechanisms: altered pre-mRNA splicing²² Cryptic splice sites in deep introns can be activated by single-nucleotide changes, diverting a fraction of transcripts toward aberrant mRNA isoforms, altered regulatory element binding affecting transcription factor access, or linkage disequilibrium with uncharacterized functional variants in the same genomic region. CYP2C9 is located on the minus strand of chromosome 10 (10q23.33); the plus-strand alleles T (reference) and C (alternate) correspond to the dbSNP-reported genotypes. The precise molecular mechanism by which the C allele influences CYP2C9 activity has not been established in functional biochemistry studies.

The Evidence

The primary pharmacogenomic evidence comes from a 2025 Indian cohort study of 144 type 2 diabetes mellitus patients stratified by HbA1c-defined drug response Mohanty et al. 2025³³ Mohanty et al. 2025
Mohanty IR et al. Association of CYP2C9, CYP2C19, CYP2C8, CYP2A6, and CYP3A4 gene polymorphism with drug response in an Indian cohort of T2DM. J Diabetes Metab Disord, 2025. The study found that rs1934963 polymorphism in CYP2C9 was significantly associated with drug response (P=0.001 across CYP2C9 genotypes), with wild-type T/T carriers demonstrating higher response rates to diabetes medications. The effect was observed alongside the established CYP2C9 variants rs2298037 and rs1057910 (*3), suggesting rs1934963 may contribute to the variance in CYP2C9 metabolizer phenotype beyond what is captured by *2 and *3 alone.

This finding is promising but must be treated cautiously: the study was small (n=144), single-centre, and the abstract does not provide individual allele frequency data or effect sizes for rs1934963 alone. No replication study and no functional characterization study have yet been published for this specific variant. It has no entry in ClinVar and is not listed as part of any named CYP2C9 star allele in PharmVar, meaning it falls outside current CPIC/DPWG pharmacogenomic guidelines.

The C allele frequency is approximately 20% globally, with modest variation across ancestries (European ~20%, African ~22%, South Asian ~15%, East Asian ~11%). This common-variant frequency is consistent with a low-penetrance modifier of CYP2C9 metabolizer status rather than a high-impact loss-of-function variant.

Practical Actions

Given the emerging evidence, individuals carrying one or two copies of the C allele should be aware that their CYP2C9 activity may be modified beyond what is predicted by the well-characterized *2 and *3 alleles. The most actionable implication is for sulfonylurea antidiabetic drugs (glipizide, glibenclamide, tolbutamide) — all CYP2C9 substrates. Reduced clearance at standard doses raises the risk of hypoglycemia, particularly in the context of any other CYP2C9 reducing factor (co-medications, other variant alleles). NSAIDs metabolized by CYP2C9 (ibuprofen, celecoxib) and warfarin may similarly be affected, though direct clinical data for these drug classes at rs1934963 are not yet available.

Interactions

rs1934963 operates within the same gene as CYP2C9*2 (rs1799853) and *3 (rs1057910). Carrying the C allele at rs1934963 alongside a *2 or *3 allele could create a compound metabolizer phenotype where total CYP2C9 activity is further reduced beyond what either variant predicts alone. No compound action study has directly measured this combination, but the pharmacological logic is consistent: multiple CYP2C9 activity-reducing variants on the same or different chromosomes sum their effect on warfarin clearance and NSAID exposure. Full CYP2C9 diplotype assessment (including all known variants) provides the most accurate metabolizer prediction for clinical dosing decisions.

The serotonin 6 receptor¹¹ serotonin 6 receptor
5-HT6R, encoded by the HTR6 gene on chromosome 1p36.13. A G protein-coupled receptor that signals via adenylate cyclase/cAMP and is expressed primarily in striatal and cortical neurons is best known in pharmacology for being inadvertently blocked by most antipsychotics and several antidepressants. But rs2050122, a variant in the regulatory region flanking HTR6, has now emerged from large-scale genome-wide association studies as a bona fide signal for chronotype — the internal timing preference that sorts people into larks and owls.

The T allele at rs2050122 is the minor allele globally (~25%) and in Europeans (~22%), while the common C allele predominates in most ancestries. GWAS data from three independent chronotype studies consistently find that the C allele is modestly associated with morning preference, meaning T-allele carriers — particularly TT homozygotes — show a slight but statistically robust shift toward eveningness.

The Mechanism

HTR6 is expressed in neurons of the striatum and frontal cortex²² striatum and frontal cortex
The striatum is the primary site of HTR6 expression; high receptor density has also been reported in the olfactory tubercle, hippocampus, and motor nuclei, where it exerts tonic inhibitory control over glutamate and acetylcholine release via Gs-mediated cAMP elevation. When 5-HT6 receptors are blocked pharmacologically, extracellular glutamate in the frontal cortex rises two- to three-fold — a finding that explains why 5-HT6 antagonists are being developed as pro-cognitive agents.

The rs2050122 variant lies in the regulatory region near HTR6. While its precise molecular effect on HTR6 expression has not been characterized at the mechanistic level, the GWAS signal maps the variant to HTR6 in multiple independent datasets. The leading biological hypothesis is that altered HTR6 expression changes serotonergic tone in the suprachiasmatic nucleus (SCN)³³ suprachiasmatic nucleus (SCN)
The master pacemaker of the circadian clock in the hypothalamus, receiving direct photic input from the retina and relaying timing information to peripheral clocks throughout the body and its downstream targets, modulating the phase or amplitude of circadian output. Serotonin is a well-established modulator of the SCN clock — it shifts the phase of SCN firing rhythms both in vitro and in vivo — but the specific HTR6 contribution to this effect is an active area of investigation.

The Evidence

Three independent chronotype GWAS studies have implicated rs2050122:

Lane et al. 2016⁴⁴ Lane et al. 2016
Lane JM et al. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. Nature Communications, 2016 was the first large-scale study to report this locus. Chronotype was assessed via self-reported morning/evening preference in over 100,000 UK Biobank participants.

Jones et al. 2016⁵⁵ Jones et al. 2016
Jones SE et al. Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics, 2016 replicated the association in 128,266 individuals combining UK Biobank and 23andMe cohorts.

The definitive study is the expanded chronotype GWAS by Jones et al. 2019⁶⁶ Jones et al. 2019
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, 2019 in nearly 700,000 individuals, which identified 351 chronotype loci and confirmed rs2050122 as a genome-wide significant signal (beta=0.031 for morningness, p=5×10⁻⁸). The per-allele effect size of ~0.031 on a normalized morningness scale translates to roughly 3–5 minutes of earlier habitual sleep timing per C allele. This is a modest individual effect, as expected for a polygenic trait, but the signal is robustly replicated.

The enrichment of chronotype GWAS hits in glutamate signaling, cAMP pathways, and brain regions co-expressing circadian and serotonin machinery is consistent with the biological plausibility of HTR6's involvement in timing.

Practical Actions

The effect size at this single locus is small — roughly 3–5 minutes of chronotype shift per allele — and TT homozygotes carry only a subtle predisposition toward eveningness. However, the T allele matters most when it compounds with other eveningness-associated variants across the genome. People with TT genotype at rs2050122 who also carry evening-associated alleles at PER2, CLOCK, or CRY1 loci may experience a more pronounced owl phenotype.

For TT carriers who report difficulty waking early, light exposure in the morning — particularly bright light therapy⁷⁷ bright light therapy
10,000 lux for 20–30 minutes within one hour of waking, the intervention studied most rigorously for chronotype shifting — is the most evidence-based behavioral intervention for phase-advancing the circadian clock, regardless of genetic cause.

Interactions

rs2050122 acts within the broader polygenic architecture of chronotype. Its effect is additive with other chronotype variants. The most studied clock gene SNPs in the GeneOps database include PER3 rs10462020 (V647G, morningness-associated under a recessive model), PER3 rs228697 (Pro864Ala), and CLOCK rs1801260 (eveningness-associated G allele). Individuals carrying the T allele at rs2050122 alongside eveningness alleles at CLOCK or PER2 may show a meaningfully earlier chronotype shift than any single variant predicts in isolation.

The pharmacological intersection is also relevant: SSRIs and many antipsychotics bind HTR6 with moderate affinity. Patients on these medications who notice disrupted sleep timing may be experiencing partial 5-HT6 modulation as a side effect. This is a gene-drug interaction worth discussing with a prescriber, particularly for TT homozygotes where background HTR6 activity may already be altered by the regulatory variant.